Friday, July 20, 2018
 
 
Company News: Page (1) of 1 - 01/02/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Dayonix Pharma expands operations into U.S marketplace
 
(January 02, 2018)
Dayonix Pharma expands operations into U.S marketplace

Dayonix Pharma, a nutraceutical, cosmetic and generic pharmaceuticals company that focuses on improving general health and prevention of specific ailments - rather than simply treating the symptoms - through the use of dietary supplements, is expanding its operations into the U.S. marketplace.

Dayonix Pharma's products vary from vitamins and minerals formulated for different age groups - ranging from newborns to grandparents - to healthcare supplements made of plant extracts that combine amino and fatty acids, minerals and vitamins. Each product intends to help prevent diseases for individuals at risk of deficiencies, as well as improve general health and wellbeing.

Dayonix Pharma already sells products throughout Europe, South Africa and other countries, and is now bringing its diverse line of products and “Live Happily" voice to the U.S.



Dayonix Pharma, based in Germany, prides itself on continuous innovation through research at its Portugal and German labs. Its most popular health supplements include Liverex, Irofix, Respigen, Crono and Viatex. These products have scientific studies backing their abilities to help improve or maintain several body systems, including liver function, the pancreatic system, blood circulation, respiratory, coronary circulation and the reproductive system.

Liverex, for example, detoxifies the liver to promote a healthy metabolism and improved digestion. Liverex does this using the nutrient choline, the antioxidant glutathione and folic acid precursor quatrefolic®.

Dayonix Pharma creates different products for different age groups. Its products for children have fruity flavors kids love, such as peach, lemon and strawberry. The most popular Kids products are Kidssi Sleep, Kidssi Appetite and Kidssi Growth, used to improve sleep, appetite and growth in children, respectively.

“Babies, children and adults have different dietary requirements and need different amounts of nutrients, including herbal extracts, to properly nourish the body," Dayonix Pharma Vice President Ricardo Correia said. “Dayonix Pharma aims to serve those who enjoy a healthy lifestyle, both for themselves and for their kids."

Dayonix Pharma works to reduce its impact on the environment, and is conscious of best environmental practices for its surrounding neighborhood, employees and customers. Most of Dayonix Pharma's products are free of sugar, artificial colors, ingredients and gluten, and the labels are all clearly marked and easy to read.

For more information on Dayonix Pharma and its products, visit http://www.dayonixpharma.com.

Read the full story at http://www.prweb.com/releases/2018/01/prweb15045184.htm.


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott
  • Trauma Fixation Global Market to Register Steady Expansion During 2018-2025
  • Global Surgical Apparel Market Will Reach USD 2,966.58 million by 2024: Zion Market Research

    Cancer
  • Mesothelioma is a Deadly Cancer and it’s Completely Preventable
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  • Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally - QYResearch.com
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines